Before + After Gallery
A board-certified plastic surgeon’s comprehensive guide to evaluation,complications, and the evolving landscape of implant options
Board-Certified Plastic Surgeon
| With millions of breast implants placed over the past five decades, a substantial and growing population of patients is living with implants well beyond their original placement — many without the benefit of regular follow-up imaging or even awareness that their devices may require attention. |
As a board-certified plastic surgeon, one of the most nuanced conversations I have is with a patient who presents with implants placed years — sometimes decades — ago. The landscape has changed considerably. We understand implant biology better. Imaging has improved. And critically, the implants themselves have improved. Managing aging implants requires a systematic understanding of what patients have, what can go wrong, and what our current options are.
Before any surgical planning, we must identify what implant is actually in the patient. This seems obvious, but patients frequently do not have their operative records, and older generation devices span a remarkably wide range of designs. Modern imaging — specifically MRI — and manufacturer registries are invaluable here.
| Implant Type | Clinical Notes |
| MOST COMMON Silicone Gel-Filled | The dominant implant type across all generations. Modern cohesive gel devices behave very differently from the liquid silicone of the 1970s–1990s era. Generation matters enormously when assessing rupture risk and MRI findings. |
| ALSO COMMON Saline-Filled | An elastomer shell filled with sterile saline at implantation. Rupture is immediately obvious — the implant deflates and the saline is absorbed harmlessly. Lower rupture surveillance burden than silicone. |
| OLDER GENERATION Dual-Lumen | A silicone inner lumen surrounded by a saline outer lumen (or vice versa). Designed for post-operative volume adjustment. Now obsolete, but still encountered in revision practices. Evaluation requires understanding both compartments. |
| RARE / HISTORICAL Polyurethane-Coated | Silicone implants coated with a polyurethane foam shell. The foam degrades over time into 2,4-toluenediamine (TDA), a compound with theoretical carcinogenic concern — though real-world incidence remains debated. |
| LESS COMMON Adjustable / Tissue Expanders | Implants with an internal or external port allowing volume adjustment post-operatively. Port identification on imaging is important before any percutaneous procedures. |
| SPECIALTY Structured Saline | IDEAL IMPLANT uses internal baffles to provide a more natural feel than conventional saline while maintaining the safety profile of saline fill. |
| CLINICAL NOTE Patients with implants from the 1980s and 1990s — particularly those with liquid silicone-filled devices — warrant heightened vigilance. These older devices have significantly higher rupture rates and the silicone is far more likely to migrate through a compromised shell. The FDA recommends MRI screening beginning 5–6 years after placement for silicone implants and every 2–3 years thereafter, though compliance remains low in this patient population. |
The complications of breast implants are well-described, but their clinical presentation spans a wide spectrum — from asymptomatic MRI findings to painful, disfiguring, and occasionally systemic conditions. Below is a structured overview of what we encounter in practice.
The fibrous capsule that naturally forms around any breast implant is a normal biological response. Capsular contracture occurs when this capsule tightens pathologically around the implant. It is classified using the Baker grading system, ranging from Grade I (imperceptible firmness) to Grade IV (painful, distorted breast with visible implant deformity).
Etiology remains debated, but subclinical infection — particularly with Staphylococcus epidermidis and other biofilm-forming organisms — is strongly implicated. Treatment for significant contracture (Grade III–IV) generally requires surgical intervention: capsulotomy (release of the capsule), capsulectomy (complete removal), or implant exchange, often with a pocket change.
Rupture epidemiology depends heavily on implant generation and device type. For silicone implants, we distinguish between intracapsular rupture — where the silicone remains contained within the fibrous capsule and is often asymptomatic — and extracapsular rupture, where silicone has extravasated beyond the capsule into surrounding tissue.
The hallmark MRI finding of silicone rupture is the “linguine sign,” representing collapsed shell folds within the gel. Saline rupture requires no imaging — the breast simply deflates within hours to days.
| IMAGE GUIDANCE MRI remains the gold standard for silicone implant rupture detection with sensitivity approaching 90% in experienced hands. Ultrasound is more accessible but operator-dependent, with lower sensitivity. Mammography is poor at rupture detection but remains part of routine breast cancer screening. When rupture is suspected clinically but imaging is equivocal, surgical exploration may be both diagnostic and therapeutic. |
When silicone migrates extracapsularly — or, in older cases, when liquid silicone was directly injected — the body mounts a foreign body giant cell reaction. These silicone granulomas can present as palpable nodules in the breast, axilla, or even distant sites including the chest wall and upper abdomen if significant migration has occurred.
On imaging, silicone granulomas can mimic malignancy. Surgical excision is often necessary for symptomatic disease, though complete removal can be challenging when migration is extensive. This is among the most surgically demanding revision scenarios we encounter.
Over time — following trauma, weight changes, pregnancy, or capsular contracture treatment — implants can migrate from their original position. Common patterns include inferior migration (bottoming out), lateral displacement, symmastia (medial migration creating a ‘uni-boob’ deformity), and rotation of shaped/anatomic implants. Correction requires pocket reconstruction, often using acellular dermal matrix (ADM) or mesh.
BIA-ALCL is a rare T-cell lymphoma arising in the seroma fluid or capsule surrounding textured implants. In 2019, Allergan voluntarily recalled its BIOCELL textured implants — the surface most strongly associated with BIA-ALCL globally. Patients with textured implants and new-onset seroma warrant urgent evaluation including fluid cytology and pathology.
Total en bloc capsulectomy — complete removal of the implant and its surrounding capsule as a single unit — is the treatment of choice for confirmed BIA-ALCL and typically results in cure without chemotherapy when disease is confined to the capsule.
Complication Overview
| Complication | Typical Presentation | Severity | Primary Intervention |
| Capsular Contracture (III–IV) | Firmness, pain, visible distortion | Moderate | Capsulectomy ± implant exchange |
| Intracapsular Rupture | Often asymptomatic; MRI finding | Low–Mod | Implant removal + exchange |
| Extracapsular Rupture | Shape change, nodularity, pain | Moderate | Capsulectomy + granuloma excision |
| Silicone Granulomas | Palpable nodules, can be distant | Moderate | Surgical excision (challenging) |
| Implant Migration | Asymmetry, positional abnormality | Low–Mod | Pocket reconstruction ± ADM |
| BIA-ALCL | Late-onset seroma (textured implants) | HIGH | En bloc capsulectomy |
| Breast Implant Illness | Systemic symptoms, variable presentation | Variable | Explantation ± capsulectomy |
Breast Implant Illness (BII) deserves thoughtful acknowledgment. Many patients present with a constellation of systemic symptoms — fatigue, cognitive difficulties, joint pain, hair loss — that they attribute to their implants. The scientific literature has not established a definitive causal mechanism, and the condition is not formally recognized as a diagnosis by major medical bodies. However, patient experience is real, and dismissal is inappropriate.
Many patients who undergo explantation report significant symptom improvement. The conversation must be honest, compassionate, and informed by the best available evidence — not by uncritical validation or reflexive skepticism.
| “The patient presenting with a twenty-year-old implant deserves the same rigor of evaluation as the primary augmentation patient — and often requires considerably more surgical judgment.” |
Revision breast surgery is, in many practices, among the most technically demanding procedures we perform. The virgin pocket of a primary augmentation is predictable. The revision field is not — it may involve dense capsule, thin, attenuated tissue, prior incisions in various locations, and the consequences of multiple previous surgeries.
The operative decision tree begins with one fundamental question: what needs to come out, and what goes back in? Capsulectomy technique — total, partial, or en bloc — is determined by the clinical indication. Extracapsular silicone migration or BIA-ALCL mandates en bloc removal with specimen integrity preserved.
Tissue quality assessment is critical. Patients with significant tissue thinning — particularly in the superior pole — may benefit from fat grafting, acellular dermal matrix support, or internal brassiere techniques. This is especially relevant in patients who have experienced weight loss, prior radiation, or have undergone multiple revisions.
After years of relative stagnation in the American implant marketplace — driven in part by the 2019 regulatory actions around textured implants and ongoing scrutiny — we are now experiencing a genuinely interesting period of expansion. Two developments in particular warrant detailed discussion.
| NOW AVAILABLE IN THE U.S. Motiva Implants: A New Standard Enters the American Market Motiva implants, manufactured by Establishment Labs, have been available in over 70 countries for years and have now received FDA approval for the U.S. market. Their arrival brings a meaningful advance in implant technology that surgeons in Europe and Latin America have long had access to. The Motiva shell is constructed using TrueMonobloc technology, creating a high-strength, uniformly thick shell with a nano-textured surface (SilkSurface). This surface sits in a unique regulatory category — nano-textured rather than conventionally textured — and carries a substantially different biofilm and BIA-ALCL profile compared to the macrotextured devices that drove the Allergan recall. The BluSeal gel formulation includes a visible blue elastomer layer incorporated into the outer shell as a rupture indicator visible to the surgeon at the time of any reoperation — a genuinely clever design feature. The Motiva Ergonomix form-stable round implant is particularly interesting: it behaves as a round implant when the patient is supine but takes a more anatomic, teardrop shape when upright due to its gel rheology. This addresses one of the classic tradeoffs between round and anatomic implants without the rotation risk inherent to shaped devices. |
| UNPRECEDENTED ACCESS Mentor Implants Above 800cc: A Genuinely Historic Development This deserves its own moment of emphasis: for the first time in U.S. regulatory history, plastic surgeons now have access to FDA-approved silicone gel breast implants in sizes exceeding 800cc. Mentor has received clearance for implants in this range, and the clinical implications are significant. Previously, patients seeking very high-volume augmentation — bodybuilders, competitive physique athletes, entertainers, and patients requiring very large volume reconstruction — were limited to on-label options or navigating off-label territory. Some were using stacked implants (placing two implants in a single pocket), a technique with a significantly elevated complication profile. Others sought care outside the United States. The availability of large-volume implants as a single, properly manufactured, FDA-approved device changes that calculus entirely. A single implant of appropriate volume is always preferable to stacked implants: one capsule, one interface, one device to monitor, and far more predictable biomechanics. Surgical note: At volumes above 600–700cc, the demands on overlying tissue become substantial. Ptosis is common, and many patients in this size range will benefit from simultaneous or staged mastopexy. Pocket selection (typically subglandular or dual-plane) and long-term follow-up planning are essential parts of the preoperative discussion. |
The patient presenting with old implants is navigating an information environment that ranges from clinical and accurate to frankly misleading. Social media has generated an enormous — and often anxiety-provoking — volume of content about breast implants, BII, BIA-ALCL, and the ‘right’ decision about whether to replace, remove, or simply monitor.
Our role as surgeons is to anchor the conversation in evidence while taking the patient’s experience seriously. A woman who had implants placed at age 28 and is now 55 is a different patient — physiologically and often philosophically — than she was at the time of her primary procedure. Her goals may have changed. Her body has changed. And what we can offer her has changed.
The consultation should cover: what implants she has (identified by operative records or imaging), whether there is evidence of rupture or other complication, her current symptoms, her understanding of the risks of action versus inaction, and — importantly — what she actually wants. Some patients want their implants out entirely. Some want them replaced with the latest technology. Some simply want reassurance that what they have is still safe to leave in place. All of these are valid outcomes of a well-conducted consultation.
| SURVEILLANCE NOTE Patients with silicone implants who have never had MRI screening should be counseled on the FDA recommendations. Intracapsular rupture is largely asymptomatic and can only be reliably detected with MRI. I routinely obtain a baseline MRI on any silicone implant patient without recent imaging, particularly if the implants are older than 10 years. |
Closing Thoughts
Managing aging breast implants is a discipline unto itself within plastic surgery. It requires encyclopedic knowledge of device history, nuanced surgical judgment, sophisticated patient communication, and an up-to-date awareness of a rapidly evolving market. We are at a genuinely interesting moment: new implant technologies have arrived, new size categories are available, and our understanding of implant-related complications continues to deepen.
For patients with old implants, the message is not one of alarm — it is one of engagement. Know what you have. Get appropriate surveillance. Have an honest conversation with a board-certified plastic surgeon who has revision experience. The tools we have today to help you are better than they have ever been.
Surgical Perspectives · Vol. XII, 2025
This article reflects the clinical perspective of a board-certified plastic surgeon and is intended for educational purposes only. It does not constitute individualized medical advice. Patients should consult with a qualified plastic surgeon for evaluation. The author has no financial relationships with any implant manufacturer referenced in this article.
